Restricted accessCase reportFirst published online 2025-12
The Tissue Systems Pathology Test Predicted Presence of Missed Neoplasia in a Patient With Non-Dysplastic Barrett’s Esophagus: A Case Report From a Foregut Surgery Center
Barrett’s esophagus (BE) is the main precursor to esophageal adenocarcinoma (EAC). Guidelines recommend endoscopic surveillance of BE to detect neoplastic progression early to improve health outcomes. It is challenging for physicians to identify BE patients that will progress to high-grade dysplasia (HGD)/EAC, and studies have shown that prevalent disease can be missed by endoscopy/pathology. The tissue systems pathology test (TSP-9) has been validated to risk stratify patients with BE by predicting their risk of progression to HGD/EAC. This report describes the clinical journey of a patient with a diagnosis of non-dysplastic (ND)BE and a high-risk TSP-9 test result, prompting risk-aligned clinical management.
WaniSFalkGHallM, et al. Patients with Nondysplastic Barrett’s Esophagus Have Low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2011;9(3):220-227; quiz e26.
3.
Critchley-ThorneRJDuitsLCPrichardJW, et al. A tissue systems pathology assay for high-risk Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2016;25(6):958-968.
4.
Critchley-ThorneRJDavisonJMPrichardJW, et al. A tissue systems pathology test detects abnormalities associated with prevalent high-grade dysplasia and esophageal cancer in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2017;26(2):240-248.
5.
DavisonJMGoldblumJGrewalUS, et al. Independent blinded validation of a tissue systems pathology test to predict progression in patients with Barrett’s Esophagus. Am J Gastroenterol. 2020;115(6):843-852.
6.
FreiNFKonteKBossartEA, et al. Independent validation of a tissue systems pathology assay to predict future progression in nondysplastic Barrett’s Esophagus: a spatial-temporal analysis. Clin Transl Gastroenterol. 2020;11(10):e00244.
7.
FreiNFKhoshiwalAMKonteK, et al. Tissue systems pathology test objectively risk stratifies barrett’s esophagus patients with low-grade dysplasia. Am J Gastroenterol. 2021;116(4):675-682.
8.
DavisonJMGoldblumJRDuitsLC, et al. A tissue systems pathology test outperforms the standard-of-care variables in predicting progression in patients with Barrett’s Esophagus. Clin Transl Gastroenterol. 2023;14(11):e00631.
9.
IyerPGCodipillyDCChandarAK, et al. Prediction of progression in Barrett’s Esophagus using a tissue systems pathology test: a pooled analysis of international multicenter studies. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2022;2020:2772-2779.
10.
DiehlDLKharaHSAkhtarNCritchley-ThorneRJ.TissueCypher Barrett’s esophagus assay impacts clinical decisions in the management of patients with Barrett’s esophagus. Endosc Int Open. 2021;9(3):E348-E355.
11.
VillaNAOrdonez-CastellanosMYodiceM, et al. The tissue systems pathology test objectively risk-stratifies patients with Barrett’s esophagus: results from a multicenter US clinical experience study. J Clin Gastroenterol. 2024;5:2.
12.
ShaheenNJFalkGWIyerPG, et al. Diagnosis and management of Barrett’s esophagus: an updated ACG guideline. Am J Gastroenterol. 2022;117(4):559-587.
13.
MuthusamyVRWaniSGyawaliCPKomanduriS, CGIT Barrett’s Esophagus Consensus Conference Participants. AGA clinical practice update on new technology and innovation for surveillance and screening in Barrett’s esophagus: expert review. Clin Gastroenterol Hepatol. 2022;20(12):2696-2706.e1.
14.
RubensteinJHSawasTWaniS, et al. AGA clinical practice guideline on endoscopic eradication therapy of Barrett’s esophagus and related neoplasia. Gastroenterology. 2024;166(6):1020-1055.
15.
SchlottmannFPattiMGShaheenNJ.Endoscopic treatment of high-grade dysplasia and early esophageal cancer. World J Surg. 2017;41(7):1705-1711.
